{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:59:26Z","timestamp":1783792766957,"version":"3.55.0"},"reference-count":146,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T00:00:00Z","timestamp":1659398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Psoriatic arthritis (PsA), a chronic inflammatory disease characterized by heterogeneous clinical manifestations, substantially impacts the quality of life of affected individuals. This article aims at developing consensus recommendations for the management of PsA and associated comorbidities and screening and monitoring requirements of PsA therapies in the United Arab Emirates (UAE) population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An extensive review of present international and regional guidelines and publications on the pharmacological management, monitoring of therapies in the context of PsA was performed. Key findings from guidelines and literature were reviewed by a panel of experts from the UAE at several meetings to align with current clinical practices. Consensus statements were formulated based on collective agreement of the experts and members of Emirates Society for Rheumatology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The consensus recommendations were developed to aid practitioners in clinical decision\u2010making with respect to dosage recommendations for pharmacological therapies for PsA, including conventional drugs, non\u2010biologic, and biologic therapies. Consensus recommendations for therapeutic options for the treatment of PsA domains, including peripheral arthritis, axial disease, enthesitis, dactylitis, psoriasis, and nail disease, were developed. The panel emphasized the importance of monitoring PsA therapies and arrived at a consensus on monitoring requirements for PsA therapies. The expert panel proposed recommendations for the management of common comorbidities associated with PsA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These consensus recommendations can guide physicians and healthcare professionals in the UAE in making proper treatment decisions, as well as efficiently managing comorbidities and monitoring therapies in patients with PsA.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.14406","type":"journal-article","created":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T09:56:55Z","timestamp":1659434215000},"page":"1107-1122","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5875-4663","authenticated-orcid":false,"given":"Khalid A.","family":"Alnaqbi","sequence":"first","affiliation":[{"name":"Department of Rheumatology Tawam Hospital  Al Ain UAE"},{"name":"College of Medicine and Health Sciences UAE University  Al Ain UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suad","family":"Hannawi","sequence":"additional","affiliation":[{"name":"Emirates Health Services (EHS)  Dubai UAE"},{"name":"Ministry of Health and Prevention  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0353-895X","authenticated-orcid":false,"given":"Rajaie","family":"Namas","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine Cleveland Clinic Abu Dhabi  UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Alshehhi","sequence":"additional","affiliation":[{"name":"Medcare Hospital  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humeira","family":"Badsha","sequence":"additional","affiliation":[{"name":"Dr. Humeira Badsha Medical Center  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7569-003X","authenticated-orcid":false,"given":"Jamal","family":"Al\u2010Saleh","sequence":"additional","affiliation":[{"name":"Dubai Hospital  Dubai UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,8,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04319-3"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22831"},{"issue":"7","key":"e_1_2_8_4_1","first-page":"1354","article-title":"Incidence and prevalence of psoriatic arthritis: a systematic review","volume":"35","author":"Alamanos Y","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.03.046"},{"issue":"2","key":"e_1_2_8_6_1","first-page":"177","article-title":"Musculoskeletal pain, disability and health\u2010seeking behavior in adult Kuwaitis using a validated Arabic version of the WHO\u2010ILAR COPCORD Core questionnaire","volume":"22","author":"Al\u2010Awadhi AM","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2016.23"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.006"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.05.010"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40726"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323001103900501"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2014.946882"},{"issue":"6","key":"e_1_2_8_15_1","first-page":"52","article-title":"GRAPPA treatment recommendations: 2021 update","volume":"49","author":"Coates LC","year":"2022","journal-title":"J Rheumatol"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14357"},{"key":"e_1_2_8_17_1","unstructured":"KaufmanMB.European commission approves upadacitinib for psoriatic arthritis & ankylosing spondylitis;2021[11\/05\/2021]. Available from:.https:\/\/www.the\u2010rheumatologist.org\/article\/european\u2010commission\u2010approves\u2010upadacitinib\u2010for\u2010psoriatic\u2010arthritis\u2010ankylosing\u2010spondylitis\/"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1857733"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2"},{"key":"e_1_2_8_20_1","unstructured":"AbbVie.AbbVie announces first regulatory approval of SKYRIZI\u2122 (risankizumab) for the treatment of plaque psoriasis generalized pustular psoriasis and erythrodermic psoriasis and psoriatic arthritis in Japan.2019[cited 26 March 2019]. Available from:https:\/\/news.abbvie.com\/news\/abbvie\u2010announces\u2010first\u2010regulatory\u2010approval\u2010skyrizi\u2010risankizumab\u2010for\u2010treatment\u2010plaque\u2010psoriasis\u2010generalized\u2010pustular\u2010psoriasis\u2010and\u2010erythrodermic\u2010psoriasis\u2010and\u2010psoriatic\u2010arthritis\u2010in\u2010japan.htm"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216835"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33161-7"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","unstructured":"MeasePDA van derHeijdeD BehrensF KivitzA KimJ.Efficacy and safety of deucravacitinib (BMS\u2010986165) an oral selective tyrosine kinase 2 inhibitor in patients with active psoriatic arthritis: results from a phase 2 randomized double\u2010blind placebo\u2010controlled trial. Abstact number LO3. ACR Convergence;2020.","DOI":"10.1136\/annrheumdis-2021-eular.2603"},{"issue":"2","key":"e_1_2_8_24_1","first-page":"272","article-title":"Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review","volume":"33","author":"Goodman SM","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"e_1_2_8_25_1","first-page":"S132","article-title":"Use of methotrexate in patients with psoriatic arthritis","volume":"28","author":"Ceponis A","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0898-2"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C"},{"issue":"5","key":"e_1_2_8_28_1","first-page":"894","article-title":"Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial","volume":"22","author":"Gupta AK","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20253"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-4097-6"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151376"},{"key":"e_1_2_8_32_1","doi-asserted-by":"crossref","unstructured":"EdwardsCBF CrowleyJ HuC StevensR BirbaraC.Long\u2010term (52\u2010week) results of a phase 3 randomized controlled trial of apremilast an oral phosphodiesterase 4 inhibitor in patients with psoriatic arthritis and current skin involvement (PALACE 3).2013. ACR\/ARHP Annual Meeting 2013.","DOI":"10.1093\/rheumatology\/keu115.006"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056"},{"key":"e_1_2_8_34_1","first-page":"3320","article-title":"A premilast in the treatment of DMARD\u2010na\u00efve psoriatic arthritis patients: results of a phase 3 randomized, controlled trial (PALACE 4).: L4","volume":"65","author":"Wells FAEC","year":"2013","journal-title":"Arthritis Rheumatism"},{"key":"e_1_2_8_35_1","first-page":"97","article-title":"Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives","volume":"9","author":"Ly K","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315582354"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S56073"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-015-0010-2"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1551-x"},{"key":"e_1_2_8_41_1","volume-title":"Administration USFaD","author":"USFDA","year":"2017"},{"key":"e_1_2_8_42_1","unstructured":"Agency EM.Skyrizi. Available from:.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/skyrizi"},{"key":"e_1_2_8_43_1","unstructured":"U.S. FDA approves second indication for SKYRIZI\u00ae (risankizumab\u2010rzaa) to treat adults with active psoriatic arthritis [press release].2022."},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0014"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0428"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000379"},{"key":"e_1_2_8_47_1","unstructured":"Agency EM.Biosimilars in EU;2017. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars\u2010eu\u2010information\u2010guide\u2010healthcare\u2010professionals_en.pdf"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom9090410"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30952-8"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724"},{"key":"e_1_2_8_51_1","unstructured":"DeodharA RR GanzF GaoT AndersonJK OsterA et al.Efficacy and safety of upadacitinib in patients with psoriatic arthritis and axial involvement. ACR Convergence 2020.2020."},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32534-6"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201681"},{"key":"e_1_2_8_56_1","unstructured":"Agency EM.Xeljanz: Pfizer Europe MA EEIG;2022. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz"},{"key":"e_1_2_8_57_1","unstructured":"U.S. FDA Approves Pfizer's XELJANZ\u00ae (tofacitinib) for the Treatment of Active Ankylosing Spondylitis. Available from:https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/us\u2010fda\u2010approves\u2010pfizers\u2010xeljanzr\u2010tofacitinib\u2010treatment\u20100"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140878"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001217"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000715"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000669"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-2055-z"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-018-0131-5"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23111"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16124"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2012.01539.x"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1801976"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0793"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03927.x"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21848"},{"issue":"1","key":"e_1_2_8_71_1","first-page":"123","article-title":"A head\u2010to\u2010head comparison of the efficacy and safety of ixekizumab and adalimumab in biological\u2010na\u00efve patients with active psoriatic arthritis: 24\u2010week results of a randomised, open\u2010label, blinded\u2010assessor trial","volume":"79","author":"Mease PJ","year":"2020","journal-title":"Rheumatol Ther"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20627"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19895492"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0001"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001519"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007393"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23930"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/714321"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00206-7"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202143"},{"issue":"5","key":"e_1_2_8_82_1","first-page":"1241","article-title":"Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms","volume":"27","author":"Scarpa R","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1329511"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000421"},{"key":"e_1_2_8_85_1","first-page":"S\u2010350","article-title":"The efficacy and safety OF guselkumab induction therapy IN patients with moderately to severely active CROHN'S disease: week 12 interim analyses from the phase 2 GALAXI 1 study","volume":"160","author":"Sandborn WJCD","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy050"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2960-8"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092585"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12744"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.052092"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000619"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.06.004"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.014"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130797"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13553"},{"issue":"8","key":"e_1_2_8_96_1","first-page":"495","article-title":"Apremilast (Otezla): a new Oral treatment for adults with psoriasis and psoriatic arthritis","volume":"40","author":"Zerilli T","year":"2015","journal-title":"P T"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003676"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170384"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13265"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205212"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00139"},{"key":"e_1_2_8_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-017-8900-8"},{"key":"e_1_2_8_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20295"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2012.00905.x"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1179\/acb.2006.028"},{"key":"e_1_2_8_106_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-017-0673-8"},{"key":"e_1_2_8_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-05029-5"},{"issue":"5","key":"e_1_2_8_108_1","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese MC","year":"2007","journal-title":"J Rheumatol"},{"issue":"4","key":"e_1_2_8_109_1","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2\u2009years of treatment with etanercept","volume":"33","author":"Mease PJ","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_8_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_8_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"issue":"5","key":"e_1_2_8_112_1","first-page":"869","article-title":"Two\u2010year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"35","author":"Antoni CE","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_8_113_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058339"},{"key":"e_1_2_8_114_1","first-page":"37","article-title":"An evidence\u2010based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy","volume":"8","author":"Acosta\u2010Felquer ML","year":"2016","journal-title":"Open Access Rheumatol"},{"key":"e_1_2_8_115_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1713754"},{"key":"e_1_2_8_116_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201411"},{"key":"e_1_2_8_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01476-3"},{"key":"e_1_2_8_118_1","unstructured":"USFDA.Taltz(ixekizumab) injection for subcutaneous use.2017. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125521s004lbl.pdf"},{"key":"e_1_2_8_119_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S148586"},{"key":"e_1_2_8_120_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963"},{"key":"e_1_2_8_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18143"},{"key":"e_1_2_8_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12453"},{"key":"e_1_2_8_123_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16798"},{"key":"e_1_2_8_124_1","doi-asserted-by":"publisher","DOI":"10.2478\/acph-2019-0047"},{"key":"e_1_2_8_125_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-004-0905-8"},{"key":"e_1_2_8_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2534-x"},{"key":"e_1_2_8_127_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/29.1.46"},{"key":"e_1_2_8_128_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurasianjmed.2021.20222"},{"key":"e_1_2_8_129_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.417"},{"key":"e_1_2_8_130_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_2_8_131_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767"},{"key":"e_1_2_8_132_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22805"},{"key":"e_1_2_8_133_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"e_1_2_8_134_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"e_1_2_8_135_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"e_1_2_8_136_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000119"},{"key":"e_1_2_8_137_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204902"},{"key":"e_1_2_8_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"e_1_2_8_139_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"},{"key":"e_1_2_8_140_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_2_8_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"e_1_2_8_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"e_1_2_8_143_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20936059"},{"key":"e_1_2_8_144_1","volume-title":"Tumor necrosis factor inhibitors","author":"Gerriets V BP","year":"2021"},{"key":"e_1_2_8_145_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000077913.60364.D2"},{"key":"e_1_2_8_146_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215356"},{"key":"e_1_2_8_147_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i28.6444"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.14406","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1756-185X.14406","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.14406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:34:21Z","timestamp":1692700461000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.14406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,2]]},"references-count":146,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1111\/1756-185X.14406"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.14406","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,2]]},"assertion":[{"value":"2022-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}